跳至主要内容
临床试验/NCT06201819
NCT06201819已完成4 期

Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery.

Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2022年12月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
37
试验地点
1
主要终点
Preoperative weight changes

研究概览

简要总结

Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.

详细描述

Objective

Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery.

Methods:

It is a single center, quasi-experimental prospective before-and-after study. All patients were assigned the same pharmacological treatment with liraglutide, initiating dosing with 0.6 mg per day escalating 0.6 mg every week up to 3.0 mg. The treatment dose was delivered once daily via subcutaneous injection for 3 months (12 weeks). Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance (BIA) final result at week 12.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with BMI greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the Bariatric and Metabolic Surgery Unit of the Civil Hospital of Guadalajara "Dr. Juan I. Menchaca

排除标准

  • Patients under 18 years of age or over 65 years of age.
  • Pregnant patients.
  • Patients who do not agree to give their consent and take part in the study.
  • Patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones.
  • Patients who decide to abandon the study.
  • Patients who do not follow the instructions or do not adhere to the treatment.

研究组 & 干预措施

Patients with morbid obesity in bariatric surgery preparation protocol

Experimental

All patients with body mass index >48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss

干预措施: Liraglutide injection (Drug)

结局指标

主要结局

Preoperative weight changes

时间窗: 3 months

Total body weight change during the drug administration

次要结局

未报告次要终点

研究者

发起方
Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jose Daniel Reyes Blandón

Bariatric Surgery Resident

Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca

研究点 (1)

Loading locations...

相似试验

招募中
4 期
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseObesity
NCT06501326Affiliated Hospital of Nantong University102
进行中(未招募)
1 期
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebo-controlled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period - SCALE™ - DiabetesObesity and overweightMedDRA version: 14.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0 Level: PT Classification code 10033307 Term: Overweight System Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2008-002199-88-GBovo Nordisk A/S
进行中(未招募)
不适用
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetesA 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period - SCALE™ - DiabetesObesity and overweightMedDRA version: 14.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.0Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2008-002199-88-SEovo Nordisk A/S800
进行中(未招募)
1 期
Effect of liraglutide on body weight in overweight orobese subjects with type 2 diabetesA 1 year randomised, double-blind, placebo-controlled,three armed parallel group, multi-centre, multinationaltrial with a 12 week observational follow-up periodObesity and overweightMedDRA version: 9.1Level: LLTClassification code 10029883Term: ObesityMedDRA version: 9.1Level: LLTClassification code 10033307Term: Overweight
EUCTR2008-002199-88-FRovo Nordisk A/S
进行中(未招募)
不适用
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetesA 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multinational trial with a 12 week observational follow-up period - SCALE™ - DiabetesObesity and overweightMedDRA version: 14.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2008-002199-88-DEovo Nordisk A/S800